26 May 2021 - This is becoming far too commonplace.

NICE has just terminated another two appraisals; both are for the same cancer medicine (ibrutinib):

• Use in combination with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma
• Use in combination with rituximab for untreated chronic lymphocytic leukaemia

Read NICE guidance and advice list